The global peptide synthesis market size was valued at USD 746.7 million in 2025. The market is projected to grow from USD 800.16 million in 2026 to USD 1,640.52 million by 2034, exhibiting a CAGR of 9.39% during the forecast period. North america dominated the peptide synthesis market with a market share of 48.59% in 2025.
Continue reading for more details:
https://www.fortunebusinessinsights.com/peptide-synthesis-market-114373
The Peptide Synthesis Market is segmented by offering into products, including peptide synthesizers, lyophilizers, chromatography systems, reagents & consumables, and services such as custom research-grade peptide synthesis and peptide library synthesis, where services dominate due to increasing outsourcing of peptide production and growing demand for large-scale therapeutic manufacturing. By method, the Peptide Synthesis Market includes solid-phase peptide synthesis, liquid-phase peptide synthesis, and others, with solid-phase peptide synthesis capturing the largest share in 2026 because of its efficiency, automation compatibility, and scalability for complex peptide production. In terms of application, the Peptide Synthesis Market is classified into therapeutics, diagnostics, and research & development, where therapeutics hold a leading share as demand for peptide-based treatments rises. Based on end-user, the market includes pharmaceutical & biotechnology companies, CROs & CDMOs, academic & research institutes, and others, with pharmaceutical & biotechnology companies accounting for a substantial portion of the Peptide Synthesis Market in 2026 due to increased peptide drug pipelines. The segmented structure of the Peptide Synthesis Market reflects how diverse offerings, synthesis methods, applications, and end-users collectively drive market adoption and investment through 2026.
• Agilent Technologies Inc.
• Thermo Fisher Scientific Inc.
• Merck KGaA
• GenScript
• Bachem AG
• Waters Corporation
• Danaher
• PolyPeptide Group
• Bio-Synthesis Inc.
• CordenPharma
The Peptide Synthesis Market is projected to grow in 2026 with the global market size expected to reach around USD 800.16 million, supported by increasing demand for peptide-based therapeutics, expanding R&D investments in peptide drug discovery, and enhanced adoption of advanced synthesis technologies in both research and commercial settings. Growth in the Peptide Synthesis Market is propelled by rising therapeutic peptide pipelines, the shift toward outsourcing production to specialized CDMOs, and increased demand for high-purity peptides in diagnostics and research applications, reinforcing the market’s expansion through 2026.
Despite positive growth trends, the Peptide Synthesis Market faces restraining factors such as technical limitations in large-scale synthesis that affect yield, purity, and process efficiency, making it challenging to scale production cost-effectively. Issues like incomplete coupling, aggregation, and racemization during synthesis, along with higher purification costs, limit the Peptide Synthesis Market’s expansion in certain segments. Additionally, complex and resource-intensive processes required for long or modified peptide chains can hamper broader adoption, especially by smaller research facilities with limited budgets.
Regionally, North America dominates the Peptide Synthesis Market in 2026 with the largest share, driven by advanced pharmaceutical R&D, strong presence of CDMOs, and high adoption of peptide-based therapies in the U.S. Europe is another major region in the Peptide Synthesis Market, with notable growth supported by investments in peptide research and therapeutic development, while Asia Pacific is experiencing robust expansion as increasing healthcare infrastructure, rising biotech activities, and growing peptide drug pipelines fuel demand. Latin America and Middle East & Africa are projected to grow at a slower pace in the Peptide Synthesis Market, but expanding research activities and increasing awareness of peptide applications are expected to drive gradual adoption in these regions through 2026.